Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents.
Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents.
复制标题
BNT162B2疫苗针对青少年关键COVID-19的有效性。
DOI：
10.1056/nejmoa2117995
复制
发表时间：
2022-02-24
期刊：
影响因子：
--
通讯作者：
Overcoming Covid-19 Investigators
中科院分区：
文献类型：
--
作者：
Olson SM;Newhams MM;Halasa NB;Price AM;Boom JA;Sahni LC;Pannaraj PS;Irby K;Walker TC;Schwartz SP;Maddux AB;Mack EH;Bradford TT;Schuster JE;Nofziger RA;Cameron MA;Chiotos K;Cullimore ML;Gertz SJ;Levy ER;Kong M;Cvijanovich NZ;Staat MA;Kamidani S;Chatani BM;Bhumbra SS;Bline KE;Gaspers MG;Hobbs CV;Heidemann SM;Maamari M;Flori HR;Hume JR;Zinter MS;Michelson KN;Zambrano LD;Campbell AP;Patel MM;Randolph AG;Overcoming Covid-19 Investigators
在美国，与由严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）的B.1.617.2（delta）变体引起的2019冠状病毒病（Covid-19）相关的儿科住院率不断增加，这为评估BNT 162 b2信使RNA疫苗在12至18岁青少年中的真实有效性提供了机会。我们采用病例对照、试验阴性设计，评估疫苗对新型冠状病毒肺炎（COVID-19）的有效性，这些有效性导致住院、入住重症监护室（ICU）、使用生命支持干预措施（机械通气、血管加压药和体外膜肺氧合）或死亡。在2021年7月1日至10月25日期间，我们在23个州的31家医院筛选了符合条件的实验室确诊新冠肺炎病例患者的入院记录。我们通过比较病例患者与两个基于医院的对照组（有Covid-19样症状但SARS-CoV-2检测结果阴性的患者（检测阴性）和没有Covid-19样症状的患者（综合征阴性））的先前完全疫苗接种（两剂BNT 162 b2）的几率来估计疫苗的有效性。共纳入445例病例患者和777例对照。总体而言，17例患者（4%）和282例对照（36%）已完全接种疫苗。在病例患者中，180例（40%）被送入ICU，127例（29%）需要生命支持; ICU中只有2例患者完全接种了疫苗。BNT 162 b2疫苗预防因Covid-19住院的总体有效性为94%（95%置信区间[CI]，90至96）;在测试阴性对照中的有效性为95%（95% CI，91至97），在综合征阴性对照中的有效性为94%（95% CI，89至96）。对ICU入院的有效性为98%，对COVID-19的有效性为98%，导致接受生命支持。所有7例死亡均发生在未接种疫苗的患者中。在住院的青少年患者中，两剂BNT 162 b2疫苗对Covid-19相关住院和ICU住院或接受生命支持非常有效。（由疾病控制和预防中心资助。
The increasing incidence of pediatric hospitalizations associated with coronavirus disease 2019 (Covid-19) caused by the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the United States has offered an opportunity to assess the real-world effectiveness of the BNT162b2 messenger RNA vaccine in adolescents between 12 and 18 years of age. We used a case–control, test-negative design to assess vaccine effectiveness against Covid-19 resulting in hospitalization, admission to an intensive care unit (ICU), the use of life-supporting interventions (mechanical ventilation, vasopressors, and extracorporeal membrane oxygenation), or death. Between July 1 and October 25, 2021, we screened admission logs for eligible case patients with laboratory-confirmed Covid-19 at 31 hospitals in 23 states. We estimated vaccine effectiveness by comparing the odds of antecedent full vaccination (two doses of BNT162b2) in case patients as compared with two hospital-based control groups: patients who had Covid-19–like symptoms but negative results on testing for SARS-CoV-2 (test-negative) and patients who did not have Covid-19–like symptoms (syndrome-negative). A total of 445 case patients and 777 controls were enrolled. Overall, 17 case patients (4%) and 282 controls (36%) had been fully vaccinated. Of the case patients, 180 (40%) were admitted to the ICU, and 127 (29%) required life support; only 2 patients in the ICU had been fully vaccinated. The overall effectiveness of the BNT162b2 vaccine against hospitalization for Covid-19 was 94% (95% confidence interval [CI], 90 to 96); the effectiveness was 95% (95% CI, 91 to 97) among test-negative controls and 94% (95% CI, 89 to 96) among syndrome-negative controls. The effectiveness was 98% against ICU admission and 98% against Covid-19 resulting in the receipt of life support. All 7 deaths occurred in patients who were unvaccinated. Among hospitalized adolescent patients, two doses of the BNT162b2 vaccine were highly effective against Covid-19–related hospitalization and ICU admission or the receipt of life support. (Funded by the Centers for Disease Control and Prevention.)